Boston Scientific said fourth quarter earnings fell 17% due to higher expenses related to its acquisition of Guidant.
Net income fell to $277 million, or 19 cents a share, from $334 million, or 40 cents per share, a year earlier.
Before exceptional items, but including stock-based comensation, the company earned 10 cents a share in the fourth quarter. Analysts were looking for 11 cents, according to Thomson Financial.
Revenue jumped 34% to $2.07 billion, in line with expectations.
Boston Scientific said that forecasting growth in its two key markets -- heart stents and implantable defibrillators -- is difficult given the volatility in those markets and so it only provided an outlook for the first quarter.
The Natick, Mass. company, which acquired Guidant last year, forecast first-quarter earnings per share of 15 to 21 cents a share, excluding special charges, amortization and stock compensation.
The company said it anticipates first-quarter sales of $2.0 billion to $2.1 billion, compared with the consensus of $2.16 billion.